Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT ID: NCT00195286
Last Updated: 2009-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2004-06-30
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
NCT00167999
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
NCT03891433
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
NCT02753946
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
NCT03687255
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
NCT01788449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
piperacillin/tazobactam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with an uncomplicated urinary tract infection
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wyeth
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antequera (Málaga), , Spain
Ávila, , Spain
Barcelona, , Spain
Berga (Barcelona), , Spain
Cadiz, , Spain
Castellon, , Spain
Cáceres, , Spain
Ciudad Real, , Spain
Cuenca, , Spain
Ferrol, , Spain
Granada, , Spain
Jaén, , Spain
Las Palmas, , Spain
Lleida, , Spain
Lorca (Murcia), , Spain
Lugo, , Spain
Madrid, , Spain
Osuna (Sevilla), , Spain
Palma Mallorca, , Spain
Pamplona, , Spain
Pontevedra, , Spain
Terrassa, , Spain
Torrelavega, , Spain
Valencia, , Spain
Valladolid, , Spain
Vitoria-Gasteiz, , Spain
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
101315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.